US Cancer Vaccine Market Outlook 2018

Description:
Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized.

Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body's natural defences against the cancer and the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer.

The vaccine market, specifically the cancer vaccine market has remained resilient to the global economic crisis in contrast to many life science sectors, which were severely impacted. Owing to drying pipelines and increasing pressure from patent expirations, the big pharma companies recognized the vaccine market as a potential resource of investment. Cancer vaccines are known to earn a higher profit than the generic drugs, owing to the nature of the disease and the urgency in the demand for these vaccines.

The US cancer vaccine market was estimated to be worth USD 14 billion in 2012. The market is expected to witness an increase of 1.5 million people being diagnosed with cancer annually. With such a rapid increase in the incidence, the US cancer vaccine market is expected to grow at a CAGR of 10% to surpass USD 20 billion by 2018. The market for cancer vaccine is in its growth stage in the US and has great opportunities for entry. The USA alone accounts for a dominating share of 50% as compared to a combined share of 50% accounted for by Europe and other regions.

"US Cancer Vaccine Market Outlook 2018" gives a comprehensive insight on following issues related to cancer vaccine market development in US:

- Cancer Incidence & Prevalence
- Cancer Vaccine Market Overview
- Cancer Vaccine Pricing & Reimbursement Policy
- Cancer Vaccine with Orphan Status
- Cancer Vaccine Pipeline by Indication & Phase
- Market Regulations
- Company Overview & Vaccine Pipeline

Contents:
1. US Cancer Incidence & Prevalence
   1.1 Leading Cancer Incidence
   1.2 Incidence by State
   1.3 Incidence by Gender
   1.4 Incidence by Age Group

2. US Cancer Vaccine Market Outlook
   2.1 Cancer Vaccine Market Overview
   2.2 Therapeutic & Prophylactic Vaccines Market
   2.3 Cancer Vaccine Pricing & Reimbursement Policy
   2.4 Cancer Vaccine with Orphan Status
   2.5 Cancer Research Funding & Grants

3. US Cancer Vaccine Market Dynamics
   3.1 Favorable Market Drivers
   3.2 Challenges to be Resolved
   3.3 Future Growth Opportunities

4. US Cancer Vaccine Pipeline by Indication
4.1 Breast Cancer
4.2 Bladder Cancer
4.3 Colorectal Cancer
4.4 Endometrial Cancer
4.5 Renal Cancer
4.6 Leukaemia
4.7 Lung Cancer
4.8 Skin Cancer
4.9 Non-Hodgkin Lymphoma
4.10 Pancreatic Cancer

5. US Cancer Vaccine Pipeline by Clinical Phase
5.1 In Development Phase: Research till Phase III
5.2 Marketed Cancer Vaccines

6. US Cancer Vaccine Market Regulations
6.1 Considerations for Both Early and Late Phase Clinical Trials
6.1.1 Patient Population
6.1.2 Monitoring The Immune Response
6.1.3 Biomarkers As Evidence Of Efficacy
6.1.4 Adjuvants Used To Stimulate Immune Response
6.1.5 Multi-Antigen Vaccines
6.1.6 Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines
6.1.7 Concomitant And Subsequent Therapies
6.2 Considerations for Early Phase Clinical Trials
6.2.1 Starting Dose And Dosing Schedule
6.2.2 Booster And Maintenance Therapy
6.2.3 Dose Escalation
6.2.4 Single-Arm Versus Randomized Phase 2 Trials In Early Development
6.3 Considerations For Late Phase Clinical Trials
6.3.1 Safety Profile From Early Phase Clinical Trials
6.3.2 Endpoints
6.3.3 Statistical Issues
6.3.4 Control Issues
6.3.5 Delayed Vaccine Effect
6.3.6 Autologous Vaccine Trials
6.3.7 Accelerated Approval Regulations

7. Competitive Landscape: Business Overview & Vaccine Pipeline
7.1 Merck & Co.
7.2 GSK
7.3 Dendreon
7.4 Aduro BioTech
7.5 Antigen Express
7.6 Bavarian Nordic
7.7 Celldex Therapeutics
7.8 Oxford BioMedica
7.9 Galena Biopharma

List Of Tables and Figures:

Table 1-1: Estimated Number of New Cases for Selected Cancers by State, 2013
Table 1-2: Estimated Number of Deaths for Selected Cancers by State, 2013
Table 1-3: Estimated Number of New Cancer Cases and Deaths by Gender, 2013
Table 1-4: Estimated New Cancer Cases by Age (years), 2013
Table 1-5: Estimated Cancer Deaths by Age (years), 2013
Table 2-1: US Orphan Designated Cancer Vaccines
Table 2-2: Spending on Cancer Research (US$ Million), 2010-2012
Table 2-3: Grants for Cancer Research (US$), 2013
Table 2-4: Grants for Cancer Research by States (US$), 2013
Table 2-5: Cancer Funding by Area of Research (US$)
Table 5-1: Marketed Cancer Vaccines: Indication & Brand Name
Table 7-1: Merck Cancer Vaccine Pipeline
Table 7-2: GSK Cancer Vaccine Pipeline
Table 7-3: Dendreon Corporation Cancer Vaccine Pipeline
Table 7-4: Aduro BioTech Cancer Vaccine Pipeline
Table 7-5: Aduro BioTech Cancer Immunotherapies
Table 7-6: Antigen Express Cancer Vaccine Pipeline
Table 7-7: Bavarian Nordic Cancer Vaccine Pipeline
Table 7-8: Celldex Therapeutics Cancer Vaccine Pipeline
Table 7-9: Oxford BioMedica Cancer Vaccine Pipeline
Table 7-10: Galena Biopharma Cancer Vaccine Pipeline

Figure 2-1: US Cancer Vaccine Market (US$ Billion), 2012-2018
Figure 2-2: US Share in Global Cancer Vaccines Market (%), 2013 & 2018
Figure 2-3: US Vaccine Market by Therapeutic & Prophylactic Vaccines, 2012 & 2018
Figure 2-4: US Prophylactic Cancer Vaccines Market, (US$ Billion), 2012-2018
Figure 2-5: US Therapeutic Cancer Vaccines Market, (US$ Billion), 2012-2018
Figure 4-1: US Cancer Vaccine Pipeline by Indication (%)
Figure 4-2: US Cancer Vaccine Pipeline by Indication (Number of Vaccines)
Figure 4-3: US Breast Cancer Vaccine Pipeline by Phase (Number of Vaccines)
Figure 4-4: US Bladder Cancer Vaccine Pipeline by Phase (Number of Vaccines)
Figure 4-5: US Colorectal Cancer Vaccine Pipeline by Phase (Number of Vaccines)
Figure 4-6: US Endometrial Cancer Vaccine Pipeline by Phase (Number of Vaccines)
Figure 4-7: US Renal Cancer Vaccine Pipeline by Phase (Number of Vaccines)
Figure 4-8: US Leukemia Cancer Vaccine Pipeline by Phase (Number of Vaccines)
Figure 4-9: US Lung Cancer Vaccine Pipeline by Phase (Number of Vaccines)
Figure 4-10: US Skin Cancer Vaccine Pipeline by Phase (Number of Vaccines)
Figure 4-11: US Non-Hodgkin Lymphoma Vaccine Pipeline by Phase (Number of Vaccines)

Figure 4-12: US Pancreatic Cancer Vaccine Pipeline by Phase (Number of Vaccines)

Figure 5-1: US Cancer Vaccine Pipeline by Clinical Phase (%)

Figure 5-2: US Cancer Vaccine Pipeline by Clinical Phase (Number of Trials)

Ordering:
Order Online - http://www.reserachandmarkets.com/reports/2753422/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information

Please verify that the product information is correct and select the format(s) you require.

Product Name: US Cancer Vaccine Market Outlook 2018
Web Address: http://www.researchandmarkets.com/reports/2753422/
Office Code: SC

Product Formats

Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hard Copy</td>
<td></td>
<td>USD 1800 + USD 61 Shipping/Handling</td>
</tr>
<tr>
<td>CD-ROM</td>
<td></td>
<td>USD 1400 + USD 61 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 1200</td>
</tr>
<tr>
<td>Electronic (PDF) - Enteprisewide</td>
<td></td>
<td>USD 2400</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.
* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information

Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ________________________________ Last Name: ________________________________
Email Address: * ________________________________
Job Title: ________________________________
Organisation: ________________________________
Address: ________________________________
City: ________________________________
Postal / Zip Code: ________________________________
Country: ________________________________
Phone Number: ________________________________
Fax Number: ________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by Wire Transfer: Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World